You will be provided with a reference and some statements. Please determine whether each statement is 'supported', 'unsupported', or 'unknown' with respect to the reference. Please note:
First, assess whether the reference contains any valid content. If the reference contains no valid information, such as a 'page not found' message, then all statements should be considered 'unknown'.
If the reference is valid, for a given statement: if the facts or data it contains can be found entirely or partially within the reference, it is considered 'supported' (data accepts rounding); if all facts and data in the statement cannot be found in the reference, it is considered 'unsupported'.

You should return the result in a JSON list format, where each item in the list contains the statement's index and the judgment result, for example:
[
    {
        "idx": 1,
        "result": "supported"
    },
    {
        "idx": 2,
        "result": "unsupported"
    }
]

Below are the reference and statements:
<reference>
TACT2: Chelation Therapy Does Not Improve Post-MI Outcomes in Patients With DM - American College of Cardiology



ACC

ACC.27-WCC

JACC

Accreditation

NCDR

Cardiosmart

MedAxiom

Create Account

Log In

Become a Member

Guidelines

DocMatter

Contact Us

Donate

Menu

Log In

About ACC

Leadership & Governance

Membership

Benefits of Your Membership

Leadership & Professional Development

Member Sections

Global Hub

Become a Member

The ACC Foundation

Advocacy

Health Equity

Innovation

Contact Us

Latest In Cardiology

News

Cardiology Magazine

Guidelines & Clinical Policy

Podcasts

Education & Meetings

Online Learning Catalog

Products

ACC Anywhere: The Cardiology Video Library

SAPs: Self-Assessment Programs

Cardiac CT

ECG Drill and Practice

Heart Songs

Nuclear Cardiology

Institutional Products

CardioSource® Plus

Leadership & Professional Development

Certificates-and-Certifications

CCKE

NP/PA-CCKE

ACC Peer Review Certificate Program

Collaborative Maintenance Pathway

Understanding MOC

Educational Catalog PDF

Meetings

Webinar - Live

Webinars - On Demand

Annual Scientific Session

Solutions & Tools

Advocacy at the ACC

Career Solutions

Clinician Well-Being

Cardiology as a Career Path

Cardiology Careers: Job Board

Clinical Solutions

Clinical Solutions for Everyday Practice

Coding & Physician Reimbursement

Infographics

Institutional Solutions

Educational Products

Equipment Buyers Guide

AI Resources

Mobile and Web Apps

Clinical Topics

Acute Coronary Syndromes

Anticoagulation Management

Arrhythmias and Clinical EP

Cardiac Surgery

Cardio-Oncology

Cardiovascular Care Team

Congenital Heart Disease and Pediatric Cardiology

COVID-19 Hub

Diabetes and Cardiometabolic Disease

Dyslipidemia

Geriatric Cardiology

Heart Failure and Cardiomyopathies

Invasive Cardiovascular Angiography and Intervention

Noninvasive Imaging

Pericardial Disease

Prevention

Pulmonary Hypertension and Venous Thromboembolism

Sports and Exercise Cardiology

Stable Ischemic Heart Disease

Valvular Heart Disease

Vascular Medicine

Become a Member

Guidelines

DocMatter

Contact Us

Donate

ACC

ACC.27-WCC

JACC

Accreditation

NCDR

Cardiosmart

MedAxiom

Create Account

< Back to Listings

Related Content

ACC.24 Meeting Coverage

Trial to Assess Chelation Therapy 2

ACC.24 Presentation Slides | TACT2

Similar Articles from ACC.org

Sep 14, 2026

|

Expert Analysis

SirPAD Redefines Drug-Coated Balloon Therapy in PAD

Sep 02, 2026

|

Podcast

Eagle’s Eye View: M-TEER Improves MR and LV Dysfunction

Aug 31, 2026

|

Expert Analysis

Advancing Equity in Maternal Cardiovascular Care From Pregnancy Through the Fourth Trimester and Beyond: Lessons from ACC.26

Aug 31, 2026

|

ACC News Story

CorCal Outcomes, EVAOLD, ISOLEDS Inform CV Risk Prediction, Post-MI Treatment and Stenting Strategies

Aug 29, 2026

|

ACC News Story

JACC Journals’ Abstracts Explore Novel Therapies, Role of Precision Medicine, and More

TACT2: Chelation Therapy Does Not Improve Post-MI Outcomes in Patients With DM

Apr 07, 2024

ACC News Story

Print

Font Size

A

A

A

On this page:

Resources

Edetate disodium-based chelation does not lead to improved outcomes in patients with diabetes who had previously suffered a myocardial infarction (MI), according to the results of the TACT2 study, presented during a Late-Breaking Clinical Trial session at
ACC.24
.

The double-blind factorial trial, conducted at 88 sites across the U.S. and Canada, randomized 959 patients (median age 67, 26.9% women, 61.5% Non-Hispanic White) with diabetes (>90% with type 2) and prior MI to either weekly edetate disodium infusions or a placebo for 40 weeks. In the treatment group, 68% of participants received all 40 infusions; 78% received at least 20.

Results showed that at a median follow-up of 48 months, there was no significant difference between the two groups in terms of the primary composite endpoint: death from any cause, MI, stroke, coronary revascularization or hospitalization for unstable angina occurred in 35% of patients in both groups (hazard ratio, 0.93; 95% CI, 0.76-1.16; p=0.53).

Researchers noted that over the same time period, serum levels of lead dropped by an average of 61% in the treatment group compared with the placebo group. Results also indicated that chelation therapy had a good safety profile. There was no increased risk of serious adverse or unexpected serious adverse events in the treatment group.

Notably, the results of the present study differ from the TACT trial, which ran from 2003 to 2012 and suggested that there were modest benefits from edetate disodium-based infusions in reducing cardiovascular events after MI over a median follow-up of 55 months, especially in patients with diabetes. Researchers speculated the reason for the differences between the two studies, which were overseen by the same study team and involved the same medications and study protocols, was the 30% lower baseline lead levels in the participants in TACT2. Furthermore, TACT2 participants may have had more advanced diabetes and severe associated health impacts than the participants of the original TACT study.

"At the present time, in a contemporary population with low lead levels, edetate disodium-based chelation is not effective as a therapy for post-heart attack patients," concluded
Gervasio A. Lamas, MD, FACC
, the study's lead author.

However, "Our method of treatment was effective at reducing lead, even in patients starting with low lead levels, and it was safe," Lamas added. "In most countries outside of North America and western Europe, lead remains a serious cardiovascular and neurological problem. This study may be more relevant to those areas of the world, but this is a hypothesis that requires further study."

Resources

ACC.24 Meeting Coverage

Trial to Assess Chelation Therapy 2

ACC.24 Presentation Slides | TACT2

Clinical Topics:

Atherosclerotic Disease (CAD/PAD)

Keywords:

ACC Annual Scientific Session,
ACC24,
Coronary Artery Disease

You must be
logged in
to save to your library.

YOU ARE HERE:

Home
>

Latest in Cardiology
>
TACT2: Chelation Therapy Does Not Improve Post-MI Outcomes in Patients With DM

About ACC

Leadership & Governance

The ACC Foundation

Advocacy

Health Equity

Innovation Program

Jobs at the ACC

Our Bylaws and Code of Ethics

Industry Relations

Book Our Conference Center

Membership

Become a Member

Renew Your Membership

Benefits of Your Membership

Member Sections

Chapters

Global Hub

ACC Member Directory

Donate Today

Latest In Cardiology

News

Cardiology Magazine

Guidelines & Clinical Policy

Podcasts

Education & Meetings

Online Learning Catalog

Products & Resources

ACC Anywhere: The Cardiology Video Library

SAPs: Self-Assessment Programs

CardioSource® Plus

Certificates & Certifications

Leadership & Professional Development

Collaborative Maintenance Pathway

Understanding MOC

Meetings

Annual Scientific Session

Solutions & Tools

Clinician Well-Being

Cardiology as a Career Path

Cardiology Careers: Job Board

Practice Solutions

Clinical Solutions for Everyday Practice

Infographics

Educational Products

Equipment Buyers Guide

AI Resources

Mobile and Web Apps

Clinical Topics

JACC Journals on ACC.org

JACC

JACC: Advances

JACC: Asia

JACC: Basic to Translational Science

JACC: CardioOncology

JACC: Cardiovascular Imaging

JACC: Cardiovascular Interventions

JACC: Case Reports

JACC: Clinical Electrophysiology

JACC: Heart Failure

JACC

NCDR

Accreditation Services

CardioSmart

MedAxiom

Contact Us

Heart House

2400 N St. NW

Washington
,

DC

20037

Contact Member Care

Phone:

1-202-375-6000

Toll Free:

1-800-253-4636

Fax:

1-202-375-6842

Media Center

Advertise With Us

Advertising & Sponsorship Policy

Press Releases

Social Media

About UX

Clinical Content Disclaimer

ACC.org Editorial Reviewers

Annual Report

Privacy Policy

Registered User Agreement

Terms of Service

Cookie Policy

Site Map

Cookie Settings

© 2026 American College of Cardiology Foundation. All rights reserved.
</reference>

<statements>
1. TACT2 (Lamas GA et al., JAMA 2024;332(10):794–803): 1,000 diabetic post-MI patients across 88 US/Canadian sites (959 received ≥1 infusion); no benefit—CV events 35.6% (chelation) vs 35.7% (placebo).
</statements>

Begin the assessment now. Output only the JSON list, without any conversational text or explanations.